Havent been following the story for a while. With management and board changes and cardio protection a now a big focus the FTO inhibition story is less visible to me. Can i tempt anyone to explain whether the lab/clinical trial process remains on track. Melanoma was an early target. As a bit of a tease: when i first started looking at this stock it showed promise as a cancer treatment of equal standing to standard of care in some setting but noted as being less damaging to heart. then that got de-emphasised as the FTO discovery took centre stage. Now the focus is cardio protection which feels more like the original story. I understand that cardio-protection could have broad application. But before cardio protection Wombat et al were talking about a drug that was bigger than Keytruda. Has the FTO opportunity been downgarded, pushed out delayed, seem less likely of scusses then a year ago. Has anything changed?
- Forums
- ASX - By Stock
- Pillar 1 - FTO (new thread)
Havent been following the story for a while. With management and...
-
-
- There are more pages in this discussion • 611 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$1.85 |
Change
-0.090(4.64%) |
Mkt cap ! $315.1M |
Open | High | Low | Value | Volume |
$1.93 | $1.97 | $1.85 | $314.6K | 164.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 44 | $1.85 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.89 | 500 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 44 | 1.850 |
2 | 8804 | 1.840 |
3 | 6774 | 1.830 |
1 | 100 | 1.820 |
6 | 12943 | 1.800 |
Price($) | Vol. | No. |
---|---|---|
1.890 | 500 | 1 |
1.910 | 2941 | 1 |
1.940 | 148 | 1 |
1.950 | 1000 | 1 |
1.975 | 2000 | 1 |
Last trade - 16.10pm 16/07/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |